Filing Analysis
Lineage Cell Therapeutics announced a registered direct offering of up to 39,473,688 common shares and warrants at $0.76 per unit. The offering includes a significant investment from Broadwood Partners, an affiliate of a board member, which requires shareholder approval.
🚩 Red Flags
- Related-party transaction: Broadwood Partners is an affiliate of Neal Bradsher, a board member.
- Significant dilution: The offering involves nearly 40 million shares at a low price point ($0.76).
- Contingent warrant expiration: Warrants expire upon specific clinical milestones (Roche/Genentech phase 2/3 trial advancement), creating complex cap table dynamics.
📋 Key Facts
- Aggregate offering size: Up to 39,473,688 common shares and accompanying warrants.
- Pricing: $0.76 per common share and one warrant per share.
- Gross proceeds: ~$24 million from unaffiliated institutional investors; ~$6 million from Broadwood Partners.
- Potential additional proceeds: Up to $36 million via future exercise of warrants.
- Warrant terms: Exercise price of $0.91; includes a milestone-based expiration linked to Roche/Genentech clinical trial advancement (OpRegen®).
- Broadwood investment requires shareholder approval due to NYSE American listing requirements regarding affiliate transactions.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 14, 2024.
📋 Key Facts
- Company announced quarterly financial results for the period ending September 30, 2024.
- The announcement was made via press release dated November 14, 2024.
- Financial results are furnished in Exhibit 99.1 and are not being filed under Section 18 of the Exchange Act.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice of the release of quarterly earnings via press release.
📋 Key Facts
- The company issued a press release on August 8, 2024, regarding financial results.
- The reporting period covered is the quarter ended June 30, 2024.
- The filing includes Exhibit 99.1 containing the full press release.
Lineage Cell Therapeutics, Inc. announced the dismissal of its independent registered public accounting firm, WithumSmith+Brown, PC, and the simultaneous engagement of Moss Adams LLP, effective June 11, 2024.
🚩 Red Flags
- Auditor change (dismissal of previous firm) is a common red flag in micro-cap biotech companies, though the company explicitly states no disagreements occurred.
📋 Key Facts
- Dismissal of WithumSmith+Brown, PC (Withum) approved by the Audit Committee on June 11, 2024.
- Engagement of Moss Adams LLP as the new independent auditor for the fiscal year ending December 31, 2024.
- Withum audited consolidated financial statements for years ended Dec 31, 2023, and Dec 31, 2022.
- The company stated there were no disagreements with Withum regarding accounting principles, practices, or auditing scope/procedures during the relevant periods.
- No reportable events occurred as defined by Item 304(a)(1)(v) of Regulation S-K.
Lineage Cell Therapeutics, Inc. filed an 8-K reporting the results of its annual meeting of shareholders held on June 11, 2024. The filing includes amendments to the company's bylaws and the ratification of the independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 11, 2024.
- Nine directors were elected to hold office until the 2025 annual meeting: Michael H. Mulroy, Dipti Amin, Deborah Andrews, Don M. Bailey, Neal C. Bradsher, Brian M. Culley, Anula Jayasuriya, Angus C. Russell, and an unnamed ninth nominee (implied by list).
- Shareholders ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for FY2024.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The Board amended and restated the Company's bylaws to conform with California Corporations Code regarding electronic meetings, emergency meetings, and shareholder nomination procedures.
Lineage Cell Therapeutics, Inc. has filed a prospectus supplement to its shelf registration statement (Form S-3) to facilitate the sale of common shares via an At-The-Market (ATM) offering. The aggregate offering price for these ATM shares is up to $39,966,424.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common shares.
- Continuous capital raising via ATM programs is often indicative of high cash burn typical in biotech/clinical-stage companies.
📋 Key Facts
- Company filed a prospectus supplement on May 14, 2024.
- The offering relates to an existing shelf registration statement (Form S-3) declared effective on May 14, 2024.
- Aggregate offering price of up to $39,966,424 in common shares.
- B. Riley Securities, Inc. is acting as the sales agent for the ATM program.
- The sale will be conducted from time to time through an At-The-Market (ATM) mechanism.
Lineage Cell Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard announcement of quarterly financial results via press release (Exhibit 99.1).
Lineage Cell Therapeutics entered into a new at-the-market (ATM) sales agreement with B. Riley Securities to sell common shares and terminated its previous ATM program with Cantor Fitzgerald. Additionally, the company reported an FDA delay in reviewing its IND for the OPC1 clinical study due to agency workload.
🚩 Red Flags
- Potential dilution through new ATM offering with B. Riley Securities.
- Regulatory delay: FDA review of IND for OPC1 is ongoing and delayed due to agency workload.
- Switching sales agents (Cantor Fitzgerald to B. Riley) often indicates a need for immediate liquidity or restructuring of financing terms.
📋 Key Facts
- Entered into a Sales Agreement with B. Riley Securities on March 22, 2024, for 'at-the-market' (ATM) offerings of common shares.
- B. Riley will receive a commission of up to 3.0% on gross proceeds from sales.
- Terminated the prior Sales Agreement with Cantor Fitzgerald & Co. effective March 18, 2024; approximately $6.66 million had been sold under that program previously.
- FDA advised Lineage not to initiate the proposed DOSED clinical study for OPC1 until receiving feedback, which is anticipated by April 26, 2024.
- The company successfully resolved an initial clinical information request from the FDA on March 18, 2024.
Lineage Cell Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 7, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Lineage Cell Therapeutics, Inc. announced the scheduling of its 2024 Annual Meeting of Shareholders for June 11, 2024. The filing outlines specific deadlines for shareholder nominations and proposals in accordance with company bylaws.
📋 Key Facts
- The 2024 Annual Meeting is scheduled for June 11, 2024.
- Shareholder notice of intention to nominate directors must be received by March 15, 2024.
- Shareholder proposals under Rule 14a-8 must be received by March 29, 2024.
- The meeting date is more than 30 days before the one-year anniversary of the 2023 annual meeting.
Lineage Cell Therapeutics, Inc. entered into a stock purchase agreement for a registered direct offering of 13,461,540 common shares at $1.04 per share. The company expects to raise approximately $14.0 million in gross proceeds to fund clinical trials, R&D, and working capital.
🚩 Red Flags
- Significant dilution: The offering of over 13 million shares at $1.04 represents a substantial increase in share count.
- Related-party involvement: Broadwood Partners, L.P. (affiliated with board member Neal Bradsher) and Don M. Bailey (board member) are participating in the offering.
📋 Key Facts
- Total shares offered: 13,461,540 common shares
- Offering price: $1.04 per share
- Expected aggregate gross proceeds: $14.0 million (before expenses)
- Closing date expected on or about February 8, 2024
- Proceeds intended for clinical trials, R&D, G&A, and working capital needs